Thromb Haemost 2002; 88(06): 1069-1071
DOI: 10.1055/s-0037-1613359
Letters to the Editor
Schattauer GmbH

Association between Sensitivity for Activated Protein C (APC) and Lipid or Lipoprotein Levels

A. J. González-Ordóñez
1   Departments of Haematology, Fundación Deportiva Municipal, Avilés, Spain
,
R. Venta
2   Biochemistry, Fundación Deportiva Municipal, Avilés, Spain
,
N. Terrados
3   Centre of Sport Medicine, Fundación Deportiva Municipal, Avilés, Spain
,
A. Arias
1   Departments of Haematology, Fundación Deportiva Municipal, Avilés, Spain
,
M. D. Macías-Robles
4   Internal Medicine, Hospital San Agustín, Fundación Deportiva Municipal, Avilés, Spain
› Author Affiliations
Further Information

Publication History

Received 12 August 2002

Accepted 28 August 2002

Publication Date:
09 December 2017 (online)

 

 
  • References

  • 1 Kawasaki T, Kambayashi J, Ariyoshi H, Sakon M, Suehisa E, Monden M. Hypercholesterolemia as a risk factor for deep-vein thrombosis. Thromb Res 1997; 88: 67-73.
  • 2 Lippi G, Guidi G. Relationship between dislipidemia and thrombosis yet unproven. Blood Coagul Fibrinolysis 2001; 12: 81-3.
  • 3 McColl MD, Sattar N, Ellison J, Tait RC, Walker ID, Packard CJ, Greer IA. Lipoprotein (a), cholesterol and triglycerides in women with venous thromboembolism. Blood Coagul Fibrinolysis 2000; 11: 225-9.
  • 4 Griffin JH, Kojima K, Banka CL, Curtiss LK, Fernández JA. High-density lipoprotein enhancement of anticoagulant activities of plasma protein S and activated protein C. J Clin Invest 1999; 103: 219-27.
  • 5 de Visser MC, Rosendaal FR, Bertina RM. A reduced sensitivity for activated protein C in the absence of factor V Leiden increases the risk of venous thrombosis. Blood 1999; 93: 1271-6.
  • 6 Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 643-50.
  • 7 van der Bom JG, Bots ML, Haverkate F, Slagboom PE, Meijer P, de Jong PT, Hofman A, Grobbee DE, Kluft C. Reduced response to activated protein C is associated with increased risk for cerebrovascular disease. Ann Intern Med 1996; 125: 265-9.
  • 8 Sampram ES, Lindblad B, Dahlback B. Activated protein C resistance in patients with peripheral vascular disease. J Vasc Surg 1998; 28: 624-9.
  • 9 Kiechl S, Muigg A, Santer P, Mitterer M, Egger G, Oberhollenzer M, Ober-hollenzer F, Mayr A, Gasperi A, Poewe W, Willeit J. Poor Response to Activated Protein C as a Prominent Risk Predictor of Advanced Atherosclerosis and Arterial Disease. Circulation 1999; 99: 614-9.
  • 10 De Ronde H, Bertina RM. Laboratory diagnosis of APC-resistance: a critical evaluation of the test and the development of diagnostic criteria. Thromb Haemost 1994; 72: 880-6.
  • 11 Griffin JH, Fernández JA, Deguchi H. Plasma lipoproteins, hemostasis and thrombosis. Thromb Haemost 2001; 86: 386-94.